{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T00:56:05Z","timestamp":1760144165320,"version":"build-2065373602"},"reference-count":16,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2019,5,1]],"date-time":"2019-05-01T00:00:00Z","timestamp":1556668800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,5,1]],"date-time":"2019-05-01T00:00:00Z","timestamp":1556668800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,6,27]],"date-time":"2020-06-27T00:00:00Z","timestamp":1593216000000},"content-version":"am","delay-in-days":423,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Revue des Maladies Respiratoires"],"published-print":{"date-parts":[[2019,5]]},"DOI":"10.1016\/j.rmr.2019.04.003","type":"journal-article","created":{"date-parts":[[2019,6,12]],"date-time":"2019-06-12T22:37:55Z","timestamp":1560379075000},"page":"583-590","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Caract\u00e9ristiques et prise en charge de l\u2019\u00e9volutivit\u00e9 c\u00e9r\u00e9bro-m\u00e9ning\u00e9e des cancers bronchiques dans un contexte de mutation activatrice"],"prefix":"10.1016","volume":"36","author":[{"given":"D.","family":"Rouviere","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R.","family":"Veillon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L.","family":"Chaltiel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Y.","family":"Simonneau","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T.","family":"Filleron","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Milia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"N.","family":"Guibert","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B.","family":"Melloni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Raherison","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Didier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Mazieres","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.rmr.2019.04.003_bib0090","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1016\/0360-3016(89)90483-5","article-title":"Identification of an optimal subgroup for treatment evaluation of patients with brain metastases using RTOG study 7916","volume":"16","author":"Diener-West","year":"1989","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.rmr.2019.04.003_bib0095","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1002\/cncr.22399","article-title":"Up-front chemotherapy and radiation treatment in newly diagnosed non small cell lung cancer with brain metastases: survey by Outcome Research Network for Evaluation of Treatment Results in Oncology","volume":"109","author":"Moscetti","year":"2007","journal-title":"Cancer"},{"key":"10.1016\/j.rmr.2019.04.003_bib0100","doi-asserted-by":"crossref","first-page":"1881","DOI":"10.1200\/JCO.2014.59.0539","article-title":"Clinical experience with crizotinib in patients with advanced alk-rearranged non-small-cell lung cancer and brain metastases","volume":"33","author":"Costa","year":"2015","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.rmr.2019.04.003_bib0105","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/j.lungcan.2015.01.020","article-title":"Brain metastases in patients with EGFR-mutated or ALK-rearranged non-small-cell lung cancers","volume":"88","author":"Rangachari","year":"2015","journal-title":"Lung Cancer"},{"key":"10.1016\/j.rmr.2019.04.003_bib0110","doi-asserted-by":"crossref","first-page":"5873","DOI":"10.1158\/1078-0432.CCR-10-1588","article-title":"Development of central nervous system metastases in patients with advanced non-small cell lung cancer and somatic EGFR mutations treated with gefitinib or erlotinib","volume":"16","author":"Heon","year":"2010","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.rmr.2019.04.003_bib0115","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1007\/s10147-014-0760-9","article-title":"Frequency of brain metastases in non-small-cell lung cancer, and their association with epidermal growth factor receptor mutations","volume":"20","author":"Iuchi","year":"2015","journal-title":"Int J Clin Oncol"},{"key":"10.1016\/j.rmr.2019.04.003_bib0120","doi-asserted-by":"crossref","first-page":"1625","DOI":"10.1097\/JTO.0000000000000318","article-title":"Patient-reported outcomes and quality of life in PROFILE 1007: a randomized trial of crizotinib compared with chemotherapy in previously treated patients with ALK-positive advanced non-small-cell lung cancer","volume":"9","author":"Blackhall","year":"2014","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.rmr.2019.04.003_bib0125","doi-asserted-by":"crossref","first-page":"e443","DOI":"10.1200\/JCO.2010.34.1313","article-title":"CSF concentration of the anaplastic lymphoma kinase inhibitor crizotinib","volume":"29","author":"Costa","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.rmr.2019.04.003_bib0130","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1093\/neuonc\/noq076","article-title":"EGFR mutation status and survival after diagnosis of brain metastasis in nonsmall cell lung cancer","volume":"12","author":"Eichler","year":"2010","journal-title":"Neuro Oncol"},{"key":"10.1016\/j.rmr.2019.04.003_bib0135","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1016\/S1470-2045(14)70362-6","article-title":"Safety and activity of alectinib against systemic disease and brain metastases in patients with crizotinib-resistant ALK-rearranged non-small-cell lung cancer (AF-002JG): results from the dose-finding portion of a phase 1\/2\u00a0study","volume":"15","author":"Gadgeel","year":"2014","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.rmr.2019.04.003_bib0140","doi-asserted-by":"crossref","first-page":"4406","DOI":"10.1158\/1078-0432.CCR-12-0357","article-title":"The impact of initial gefitinib or erlotinib versus chemotherapy on central nervous system progression in advanced non-small cell lung cancer with EGFR mutations","volume":"18","author":"Heon","year":"2012","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.rmr.2019.04.003_bib0145","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1093\/annonc\/mds529","article-title":"Erlotinib as second-line treatment in patients with advanced non-small-cell lung cancer and asymptomatic brain metastases: a phase II study (CTONG-0803)","volume":"24","author":"Wu","year":"2013","journal-title":"Ann Oncol"},{"key":"10.1016\/j.rmr.2019.04.003_bib0155","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1016\/j.lungcan.2012.05.092","article-title":"Efficacy of epidermal growth factor receptor tyrosine kinase inhibitors for brain metastasis in non-small cell lung cancer patients harboring either exon 19\u00a0or 21\u00a0mutation","volume":"77","author":"Park","year":"2012","journal-title":"Lung Cancer Amst Neth"},{"key":"10.1016\/j.rmr.2019.04.003_bib0160","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.lungcan.2008.10.016","article-title":"Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) are effective for leptomeningeal metastasis from non-small cell lung cancer patients with sensitive EGFR mutation or other predictive factors of good response for EGFR TKI","volume":"65","author":"Yi","year":"2009","journal-title":"Lung Cancer"},{"key":"10.1016\/j.rmr.2019.04.003_bib0165","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1097\/JTO.0b013e318294c8e8","article-title":"Erlotinib versus gefitinib for control of leptomeningeal carcinomatosis in non-small-cell lung cancer","volume":"8","author":"Lee","year":"2013","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.rmr.2019.04.003_bib0080","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.lungcan.2012.12.016","article-title":"First case report of intrathecal panitumumab for treatment of meningeal carcinomatousis in an EGFR mutant lung adenocarcinoma patient","volume":"80","author":"Hollebecque","year":"2013","journal-title":"Lung Cancer"}],"container-title":["Revue des Maladies Respiratoires"],"original-title":[],"language":"fr","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0761842519301366?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0761842519301366?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T14:19:29Z","timestamp":1760105969000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0761842519301366"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,5]]},"references-count":16,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2019,5]]}},"alternative-id":["S0761842519301366"],"URL":"https:\/\/doi.org\/10.1016\/j.rmr.2019.04.003","relation":{},"ISSN":["0761-8425"],"issn-type":[{"type":"print","value":"0761-8425"}],"subject":[],"published":{"date-parts":[[2019,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Caract\u00e9ristiques et prise en charge de l\u2019\u00e9volutivit\u00e9 c\u00e9r\u00e9bro-m\u00e9ning\u00e9e des cancers bronchiques dans un contexte de mutation activatrice","name":"articletitle","label":"Article Title"},{"value":"Revue des Maladies Respiratoires","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.rmr.2019.04.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 SPLF. Published by Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}